Ezra Holdings Limited (NASDAQ:EZRA) Stock Short Interest Drops 64.9%

Ezra Holdings Limited (NASDAQ:EZRA) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 18,115 shares, a decrease of 64.9% from the August 31st total of 51,669 shares. Based on an average trading volume of 48,815 shares, the short-interest ratio is presently 0.4 days.

Insiders Place Their Bets

In other Ezra news, Director Alex Blumenfrucht sold 8,830 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $3.97, for a total transaction of $35,055.10. Following the completion of the sale, the director owned 13 shares of the company’s stock, valued at $51.61. This trade represents a 99.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Yaakov Beyman sold 9,120 shares of Ezra stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $3.83, for a total value of $34,929.60. Following the completion of the sale, the vice president owned 2,967 shares in the company, valued at $11,363.61. This represents a 75.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 34,727 shares of company stock valued at $124,161 over the last quarter.

Ezra Price Performance

Ezra stock traded down $0.02 during midday trading on Monday, reaching $2.66. 5,247 shares of the stock traded hands, compared to its average volume of 804,685. The business has a 50-day simple moving average of $2.53. Ezra has a 12-month low of $1.75 and a 12-month high of $53.20.

Ezra (NASDAQ:EZRA) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($3.26) earnings per share (EPS) for the quarter. The firm had revenue of $2.11 million for the quarter.

Analyst Ratings Changes

A number of research firms have commented on EZRA. Wall Street Zen cut shares of Ezra from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Weiss Ratings raised shares of Ezra from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Ezra Company Profile

Ezra (NASDAQ: EZRA) is a health care technology company focused on improving cancer screening and early detection. The company combines magnetic resonance imaging (MRI) with artificial intelligence to help identify potential cancer and other abnormalities, with the goal of making screening more accessible, efficient and comprehensive.

Its services include Ezra Screen, an MRI-based screening program designed to examine multiple areas of the body in a single session, as well as related imaging and cancer-screening services.